IMTX Immatics NV: Multiplikator nilai perusahaan marang pendapatan

Logo perusahaan publik immatics.com (IMTX)

The intellectual capital of Immatics N.V. (IMTX) is based on the discovery of tumor targets for T-cell therapy. The EV/Revenue multiple demonstrates stable dynamics, with the metric currently standing at 8072.08. Financial stability is supported by payments from pharma partners and flawless cold chain control during drug delivery, which guarantees high profitability and protects the company from market volatility.

Nilai perusahaan marang pendapatan: Immatics NV (IMTX) kanggo 23.11.2025 - 20.11.2026

immatics.com - rincian analitis lan metrik utama (IMTX)

- rega saham lan konsensus proyeksi valuasi:
Analisis wiwitan perusahaan:Immatics N.V. IMTX
Sampel barang Immatics N.V.

The innovative T-cell receptor ecosystem of Immatics N.V. (IMTX) creates high added value within the precision oncology segment. The current EV/Sales ratio reflects the enterprise value of the business, accounting for net debt relative to generated revenue. This metric allows for an assessment of the capitalization efficiency of the company's technological advantage without distortions from debt load. The indicator serves as a filter to separate fundamental growth from speculative volatility. Analyzing the trend of the current EV/Sales ratio helps determine the fair value of the assets.

Analisis pesaing Immatics N.V.

IBRX (immunitybio.com) - Rasio nilai perusahaan marang pendapatan|Immunocore Corp (IMCR) - Rasio nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Janux Pharma (JANX)|Nilai perusahaan marang pendapatan RCUS|ZYME - Rasio nilai perusahaan marang dodolan|Nilai perusahaan marang pendapatan TNGX (Tango Pharma)|Koefisien nilai perusahaan marang pendapatan IOVA|Multiplikator EV/Sales XNCR (Xencor)|Nilai bisnis marang pendapatan CMPX|replimune.com - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Lyell Pharma|Innate Pharma S.A. (IPHA) - Rasio nilai perusahaan marang pendapatan|Pyxis Oncology Inc. - Nilai bisnis marang pendapatan|CGEN (Compugen Limited) - Multiplikator EV/Sales|Multiplikator EV/Sales IO Biotech Inc|Rasio nilai perusahaan marang pendapatan Sutro Biopharma (STRO)|INKT: Nilai perusahaan marang volume dodolan|Werewolf Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Immix (IMMX) - Multiplikator nilai perusahaan marang pendapatan|ALX Oncology Holdings Inc. - Multiplikator EV/Sales|CUE - Multiplikator EV/Sales|PDSB: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - Multiplikator EV/Sales|Nilai perusahaan marang pendapatan Liminatus Pharma (LIMN)|Multiplikator EV/Sales LVTX|Koefisien nilai perusahaan marang pendapatan NXTC|Leap Therapeutics, Inc. - Nilai perusahaan marang pendapatan|INTS: Rasio nilai perusahaan marang pendapatan|Sensei Biotherapeutics Inc - Multiplikator EV/Sales|TOVX: Rasio nilai perusahaan marang pendapatan|gritstonebio.com (GRTS) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan KA|Rasio nilai perusahaan marang pendapatan NexImmune, Inc.|Rasio nilai perusahaan marang pendapatan TSBX (Turnstone Biologics)|Nilai perusahaan marang pendapatan VCNX (Vaccinex, Inc.)|Koefisien nilai perusahaan marang pendapatan HARP